



**New York State Medicaid
Preferred Drug Program
2017 Therapeutic Class Review**

The New York Medicaid Drug Utilization Review (DUR) Board intends to review the following therapeutic classes in 2017 as they pertain to the fee-for-service (FFS) Preferred Drug Program (PDP). For the therapeutic classes (provided below), new relevant clinical and/or financial information since the previous review of the class is known to exist. DUR Board meeting agendas for 2017 are posted to the Department of Health (DoH) web-site thirty days prior to the meeting date.

Therapeutic Category	Therapeutic Class	Previous Review Date
Analgesics	Opioids - Long Acting	April 27, 2016
Anti-Infectives	Hepatitis B Agents	Initial Review
Cardiovascular	Angiotensin Converting Enzyme Inhibitors	April 22, 2015
	HMG-CoA Reductase Inhibitors (Statins)	April 19, 2012
Central Nervous System	Anticonvulsants - Second Generation	September 15, 2016
	Antipsychotics - Second Generation	April 27, 2016
	Central Nervous System Stimulants	April 27, 2016
	Multiple Sclerosis Agents	September 15, 2016
Dermatological Agents	Antifungals - topical	April 24, 2014
	Anti-Infectives - topical	April 24, 2014
Endocrine and Metabolic Agents	Glucagon-like Peptide-1 Agonists	April 22, 2015
	Glucocorticoids - Oral	June 27, 2013
	Insulin, Long-Acting	April 27, 2016
	Sodium Glucose Co-Transporter 2 Inhibitors	September 18, 2014

Hematologicals	Anticoagulants - Oral	April 22, 2015
	Platelet Inhibitors	September 17, 2015
Miscellaneous	Epinephrine, self-injected	Initial Review
Ophthalmics	Non-Steroidal Anti-Inflammatory Drugs, Ophthalmic	June 27, 2013
Otics	Fluoroquinolones - Otic	June 10, 2009
Renal and Genitourinary	Phosphate Binders/Regulators	April 22, 2015
Respiratory	Anticholinergics - COPD Agents	April 27, 2016
	Corticosteroid/LA Beta-2 Adrenergic Agent Combinations - Inhaled	April 24, 2014
	Corticosteroids - Intranasal	April 24, 2014

The current preferred and non-preferred status of drugs subject to the PDP may be viewed at https://newyork.fhsc.com/downloads/providers/NYRx_PDP_PDL.pdf

At this time, no relevant new clinical and/or financial information is known to exist for the remaining PDP therapeutic classes since previously reviewed and the DoH proposes no changes to the Preferred Drug List (PDL). If interested parties have new relevant clinical information, please submit to the Medicaid Pharmacy Department (dur@health.ny.gov) in a timely manner. The DoH will consider any new relevant clinical information provided when developing future DUR Board meeting agendas.

In determining new clinical information, the previous review dates for all therapeutic classes are available on prior meeting agendas which may be viewed at http://www.health.ny.gov/health_care/medicaid/program

New clinical information may include a new drug or drug product information, new indications, new safety information or new published clinical trials. Comparative evidence is preferred, or placebo controlled when no head-to-head trials are available. Information in abstract form alone, posters, or unpublished data are poor quality evidence for the purpose of review and submission is discouraged.

Those wishing to submit new clinical information may do so as it becomes available. New information is preferred in an electronic format and may be submitted to dur@health.ny.gov (please reference DUR Board PDP Review).

Please continue to monitor the DoH web-site for DUR Board meeting schedules and agendas at http://www.health.ny.gov/health_care/medicaid/program/pharmacy.htm